[go: up one dir, main page]

WO2009028417A1 - 婦人科癌の検出方法 - Google Patents

婦人科癌の検出方法 Download PDF

Info

Publication number
WO2009028417A1
WO2009028417A1 PCT/JP2008/065014 JP2008065014W WO2009028417A1 WO 2009028417 A1 WO2009028417 A1 WO 2009028417A1 JP 2008065014 W JP2008065014 W JP 2008065014W WO 2009028417 A1 WO2009028417 A1 WO 2009028417A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
detection method
ovarian cancer
gynecologic cancer
gynecologic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065014
Other languages
English (en)
French (fr)
Inventor
Katsuko Yamashita
Akira Seko
Daisuke Aoki
Masaru Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Institute of Technology NUC
Original Assignee
Tokyo Institute of Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Institute of Technology NUC filed Critical Tokyo Institute of Technology NUC
Priority to US12/674,875 priority Critical patent/US20110306049A1/en
Priority to EP08828673.7A priority patent/EP2187217B1/en
Priority to JP2009530083A priority patent/JP5345059B2/ja
Priority to CN200880105112.6A priority patent/CN101828114B/zh
Priority to ES08828673T priority patent/ES2434958T3/es
Priority to CA2697508A priority patent/CA2697508A1/en
Publication of WO2009028417A1 publication Critical patent/WO2009028417A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　本発明の課題は、婦人科癌、特には卵巣癌又は子宮体癌の検出方法及び検出用キットを提供することにある。 　本発明の課題は、β１－３ガラクトース転移酵素－５及び／又はβ１－３ガラクトース転移酵素－４、並びにＮ－アセチルグルコサミン６－Ｏ－硫酸転移酵素－２を分析することを特徴とする婦人科癌、特には卵巣癌又は子宮体癌の検出方法によって解決できる。本発明の検出方法により、自覚症状の見られない、卵巣癌の病期の初期のステージであるＩ期及びII期において、高率に卵巣癌患者を検出することが可能であり、また子宮体癌患者を検出することが可能である。
PCT/JP2008/065014 2007-08-24 2008-08-22 婦人科癌の検出方法 Ceased WO2009028417A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/674,875 US20110306049A1 (en) 2007-08-24 2008-08-22 Method for detecting gynecologic cancer
EP08828673.7A EP2187217B1 (en) 2007-08-24 2008-08-22 Detection method of gynecologic cancer
JP2009530083A JP5345059B2 (ja) 2007-08-24 2008-08-22 婦人科癌の検出方法
CN200880105112.6A CN101828114B (zh) 2007-08-24 2008-08-22 妇科癌症的检出方法
ES08828673T ES2434958T3 (es) 2007-08-24 2008-08-22 Método para detectar cáncer ginecológico
CA2697508A CA2697508A1 (en) 2007-08-24 2008-08-22 Method for detecting gynecologic cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007219046 2007-08-24
JP2007-219046 2007-08-24
JP2008063641 2008-03-13
JP2008-063641 2008-03-13

Publications (1)

Publication Number Publication Date
WO2009028417A1 true WO2009028417A1 (ja) 2009-03-05

Family

ID=40387139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065014 Ceased WO2009028417A1 (ja) 2007-08-24 2008-08-22 婦人科癌の検出方法

Country Status (7)

Country Link
US (1) US20110306049A1 (ja)
EP (1) EP2187217B1 (ja)
JP (1) JP5345059B2 (ja)
CN (1) CN101828114B (ja)
CA (1) CA2697508A1 (ja)
ES (1) ES2434958T3 (ja)
WO (1) WO2009028417A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008494A1 (ja) * 2010-07-16 2012-01-19 独立行政法人国立がん研究センター 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
WO2013015363A1 (ja) 2011-07-26 2013-01-31 独立行政法人産業技術総合研究所 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法
WO2013015367A1 (ja) 2011-07-26 2013-01-31 独立行政法人産業技術総合研究所 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2013152301A1 (en) * 2012-04-05 2013-10-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. O-glycan pathway ovarian cancer signature
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
DE102013020391A1 (de) * 2013-12-10 2015-06-11 Polysecure Gmbh Markierter Schichtaufbau, Verfahren zu dessen Herstellung und Verwendung desselben
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267052A1 (en) 2014-05-27 2016-12-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
CN107001404B (zh) 2014-09-08 2021-06-29 中央研究院 使用醣脂激活人类iNKT细胞
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050608A1 (en) 1999-02-25 2000-08-31 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2888587B2 (ja) * 1990-03-06 1999-05-10 コニカ株式会社 癌関連ヒト由来ガラクトース転移酵素に特異的なモノクローナル抗体、それを産生するハイブリドーマ及びそれを用いた検体中の癌関連ヒト由来ガラクトース転移酵素の測定方法
US5955282A (en) * 1998-04-03 1999-09-21 Incyte Pharmaceuticals, Inc. Human galactosyltransferases
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
FR2847194B1 (fr) * 2002-11-19 2005-02-04 Iniversite Catholique De Louva Procede de creation de pores dans une feuille mince de polyimide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050608A1 (en) 1999-02-25 2000-08-31 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptide

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AKIRA KANOH ET AL.: "Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.", GLYCOCONJUGATE J., vol. 23, no. 5-6, 2006, pages 453 - 460, XP019396409 *
E.V.CHANDRASEKARAN ET AL.: "Mucin biosynthesis revisited, The enzymatic transfer of Gal in beta1,3 linkage to the GalNAc moiety of the core structure R1-GlcNAcβ1,6GalNAcα-O-R2", J.BIOL.CHEM., vol. 267, no. 28, 1992, pages 19929 - 19937, XP055352161 *
JUNKO YOSHIKI ET AL.: "High expression of uridine diphosphate-galactose:Lc3Cer beta1-3 Galactosyltransferase in human uterine endometrial cancer-derived cells as measured by enzyme-linked immunosorbent assay and thin layer chromatography-immunostaining.", JPN.J. CANCER RES., vol. 88, no. 7, 1997, pages 669 - 677, XP009136982 *
KANOH A. ET AL., GLYCOCONJUGATE JOURNAL, vol. 23, 2006, pages 453 - 460
KOHLER, G., MILSTEIN, C., NATURE, vol. 256, 1975, pages 495 - 497
LYDIA MARE ET AL.: "Suppression of beta1,3 galactosyltransferase beta3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans", EUR.J. BIOCHEM., vol. 271, no. 1, 2004, pages 186 - 194, XP003026506 *
MIYAZAKI ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 24794 - 24799
NOBUYASU HAYASHI ET AL.: "Association between expression levels of CA 19-9 and N-Acetylglucosamine-beta1,3-galactosyltransferases gene in human pancreatic cancer tissue.", PATHOBIOLOGY, vol. 71, no. 1, 2004, pages 26 - 34, XP008125175 *
See also references of EP2187217A4
SEKO A. ET AL., GLYCOBIOLOGY, vol. 12, 2002, pages 379 - 388
SEKO ET AL., CANCER RES., vol. 56, 1996, pages 3468 - 3473
SEKO ET AL., GLYCOBIOLOGY, vol. 12, 2002, pages 379 - 388
SEKO.A., CANCER RESEARCH, vol. 56, 1996, pages 3468 - 3473
SOICHIRO ISSHIKI ET AL.: "Cloning, expression, and characterization of a novel UDP-galactose:beta-N-acetylglucosamine beta1,3-galactosyltransferase(beta3Gal-T5) responsible for synthesis of type 1 chain in colorectal and pancreatic epithelia and tumor cells derived therefrom", J.BIOL.CHEM., vol. 274, no. 18, 1999, pages 12499 - 12507, XP002928039 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008494A1 (ja) * 2010-07-16 2012-01-19 独立行政法人国立がん研究センター 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
WO2013015363A1 (ja) 2011-07-26 2013-01-31 独立行政法人産業技術総合研究所 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法
WO2013015367A1 (ja) 2011-07-26 2013-01-31 独立行政法人産業技術総合研究所 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法
US9816996B2 (en) 2011-07-26 2017-11-14 National Institute Of Advanced Industrial Science And Technology Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer
US10247733B2 (en) 2011-07-26 2019-04-02 National Institute Of Advanced Industrial Science And Technology Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer

Also Published As

Publication number Publication date
CN101828114B (zh) 2015-03-11
CA2697508A1 (en) 2009-03-05
EP2187217A4 (en) 2010-09-15
CN101828114A (zh) 2010-09-08
ES2434958T3 (es) 2013-12-18
JPWO2009028417A1 (ja) 2010-12-02
US20110306049A1 (en) 2011-12-15
JP5345059B2 (ja) 2013-11-20
EP2187217B1 (en) 2013-11-06
EP2187217A1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
WO2009028417A1 (ja) 婦人科癌の検出方法
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
CA2755394C (en) Methods and compositions for cell-proliferation-related disorders
WO2007082154A3 (en) B7-h1 and b7-h4 in cancer
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
MX2010003424A (es) Medicion de propiedades mecanicas.
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2011143361A3 (en) Methods and compositions for diagnosing conditions
WO2009036427A3 (en) Prostate cancer biomarkers
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2012021407A3 (en) Biomarkers for stroke
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
WO2010056374A3 (en) Methods and compositions of molecular profiling for disease diagnostics
WO2010088668A3 (en) Methods of detecting sepsis
WO2007140352A3 (en) Plasma membrane and secreted cancer biomarkers
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
WO2013003815A3 (en) Near-infrared fluorescent dyes with large stokes shifts
WO2012058313A3 (en) Novel biomarkers for cardiovascular injury
WO2009114756A3 (en) Biomarkers for inflammatory bowel disease and irritable bowel syndrome
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880105112.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828673

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009530083

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12674875

Country of ref document: US

Ref document number: 2697508

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008828673

Country of ref document: EP